

# Cutaneous adverse reactions in B-RAF positive metastatic melanoma treated with B-RAF/MEK inhibitors and immune checkpoint inhibitors: a single-institutional case-series

DOI: [10.1186/s40425-018-0475-y](https://doi.org/10.1186/s40425-018-0475-y)

Citation Report

#	ARTICLE	IF	CITATIONS
1	A patent review of RAF kinase inhibitors (2010–2018). <i>Expert Opinion on Therapeutic Patents</i> , 2019, 29, 675-688.	2.4	13
3	Atypical features of cutaneous adverse drug reactions during therapy for hairy cell leukemia. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 3203-3206.e1.	2.0	4
4	Systematic review of BRAF/MEK inhibitors–induced Severe Cutaneous Adverse Reactions (SCARs). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 607-614.	1.3	26
5	Posterior Reversible Encephalopathy Syndrome (PRES) and Drug-Induced Hypersensitivity Syndrome (DIHS) following Immunotherapy and BRAF/MEK Inhibition with Continued Response in Metastatic Melanoma. <i>Case Reports in Oncological Medicine</i> , 2021, 2021, 1-5.	0.2	4
6	Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study. <i>Frontiers in Oncology</i> , 2021, 11, 672172.	1.3	2
7	Drug-induced hypersensitivity syndrome like reaction with angioedema and hypotension associated with BRAF inhibitor use and antecedent immune checkpoint therapy. <i>JAAD Case Reports</i> , 2021, 13, 147-151.	0.4	4
8	Maculopapular erythema caused by previously used chemotherapy drugs after nivolumab treatment for malignant mesothelioma. <i>Journal of Cutaneous Immunology and Allergy</i> , 2021, 4, 178-180.	0.2	0
9	Clinical features of drug-induced hypersensitivity syndrome to BRAF inhibitors with and without previous immune checkpoint inhibition: a review. <i>Supportive Care in Cancer</i> , 2022, 30, 2839-2851.	1.0	1
10	Dress syndrome secondary to different combinations of targeted therapy (iBRAF + iMEK). <i>European Journal of Dermatology</i> , 2020, 30, 303-304.	0.3	2
11	Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2021, 39, 4073-4126.	0.8	580
12	Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy. <i>BMC Cancer</i> , 2021, 21, 1187.	1.1	6
13	Stevens-Johnson Syndrome and Severe Anaemia: A Case of Toxicity Induced by Vemurafenib plus Cobimetinib following Pembrolizumab for Metastatic Melanoma. <i>Acta Dermato-Venereologica</i> , 2022, , .	0.6	1
14	Morphologic characteristics of cutaneous immune-related adverse events in patients receiving immune checkpoint inhibitors combined with other anticancer therapies: A multicenter retrospective study. <i>Journal of the American Academy of Dermatology</i> , 2023, 88, 474-476.	0.6	0
15	Cutaneous Reactions to Oncologic Immunotherapy. <i>Updates in Clinical Dermatology</i> , 2022, , 317-330.	0.1	0
16	Etanercept leads to a rapid recovery of a Dabrafenib–Trametinib-associated toxic epidermal necrolysis–like severe skin reaction. <i>Skin Health and Disease</i> , 0, , .	0.7	0